DE19906096A1 - Protein mit einem Heparin-bindenden Epitop - Google Patents
Protein mit einem Heparin-bindenden EpitopInfo
- Publication number
- DE19906096A1 DE19906096A1 DE19906096A DE19906096A DE19906096A1 DE 19906096 A1 DE19906096 A1 DE 19906096A1 DE 19906096 A DE19906096 A DE 19906096A DE 19906096 A DE19906096 A DE 19906096A DE 19906096 A1 DE19906096 A1 DE 19906096A1
- Authority
- DE
- Germany
- Prior art keywords
- protein
- heparin
- sequence
- tgf
- proteins
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 title claims abstract description 19
- 229920000669 heparin Polymers 0.000 title claims abstract description 19
- 229960002897 heparin Drugs 0.000 title claims abstract description 19
- 108090000623 proteins and genes Proteins 0.000 title claims description 59
- 102000004169 proteins and genes Human genes 0.000 title claims description 57
- 150000001413 amino acids Chemical class 0.000 claims description 27
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims description 20
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims description 20
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims description 19
- 210000000988 bone and bone Anatomy 0.000 claims description 7
- 206010007710 Cartilage injury Diseases 0.000 claims 1
- 230000008468 bone growth Effects 0.000 claims 1
- 229940126601 medicinal product Drugs 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 abstract description 5
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 5
- 108090000765 processed proteins & peptides Proteins 0.000 abstract description 5
- 238000000034 method Methods 0.000 abstract description 4
- 230000011164 ossification Effects 0.000 abstract description 2
- 102000039446 nucleic acids Human genes 0.000 abstract 2
- 108020004707 nucleic acids Proteins 0.000 abstract 2
- 150000007523 nucleic acids Chemical class 0.000 abstract 2
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 230000022159 cartilage development Effects 0.000 abstract 1
- 238000003780 insertion Methods 0.000 abstract 1
- 230000037431 insertion Effects 0.000 abstract 1
- 230000000638 stimulation Effects 0.000 abstract 1
- 238000006467 substitution reaction Methods 0.000 abstract 1
- 230000029663 wound healing Effects 0.000 abstract 1
- 235000018102 proteins Nutrition 0.000 description 47
- 235000001014 amino acid Nutrition 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 11
- 102000005962 receptors Human genes 0.000 description 11
- 108020003175 receptors Proteins 0.000 description 11
- 108091033319 polynucleotide Proteins 0.000 description 5
- 102000040430 polynucleotide Human genes 0.000 description 5
- 239000002157 polynucleotide Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 4
- 108010049931 Bone Morphogenetic Protein 2 Proteins 0.000 description 3
- 102100024506 Bone morphogenetic protein 2 Human genes 0.000 description 3
- 102000009618 Transforming Growth Factors Human genes 0.000 description 3
- 108010009583 Transforming Growth Factors Proteins 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000000845 cartilage Anatomy 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 108010049870 Bone Morphogenetic Protein 7 Proteins 0.000 description 2
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 description 2
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 description 2
- 102100022544 Bone morphogenetic protein 7 Human genes 0.000 description 2
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- 108010090254 Growth Differentiation Factor 5 Proteins 0.000 description 2
- 102100035379 Growth/differentiation factor 5 Human genes 0.000 description 2
- 102000016611 Proteoglycans Human genes 0.000 description 2
- 108010067787 Proteoglycans Proteins 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 229940112869 bone morphogenetic protein Drugs 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 229960003067 cystine Drugs 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 102000035118 modified proteins Human genes 0.000 description 2
- 108091005573 modified proteins Proteins 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- UBWXUGDQUBIEIZ-UHFFFAOYSA-N (13-methyl-3-oxo-2,6,7,8,9,10,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-17-yl) 3-phenylpropanoate Chemical compound CC12CCC(C3CCC(=O)C=C3CC3)C3C1CCC2OC(=O)CCC1=CC=CC=C1 UBWXUGDQUBIEIZ-UHFFFAOYSA-N 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- 102000005606 Activins Human genes 0.000 description 1
- 108010059616 Activins Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102000001893 Bone Morphogenetic Protein Receptors Human genes 0.000 description 1
- 108010040422 Bone Morphogenetic Protein Receptors Proteins 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 229920000045 Dermatan sulfate Polymers 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 229920002971 Heparan sulfate Polymers 0.000 description 1
- 102000002746 Inhibins Human genes 0.000 description 1
- 108010004250 Inhibins Proteins 0.000 description 1
- LFVLUOAHQIVABZ-UHFFFAOYSA-N Iodofenphos Chemical compound COP(=S)(OC)OC1=CC(Cl)=C(I)C=C1Cl LFVLUOAHQIVABZ-UHFFFAOYSA-N 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 102000002278 Ribosomal Proteins Human genes 0.000 description 1
- 108010000605 Ribosomal Proteins Proteins 0.000 description 1
- 102000007453 TGF-beta Superfamily Proteins Human genes 0.000 description 1
- 108010085004 TGF-beta Superfamily Proteins Proteins 0.000 description 1
- 239000000488 activin Substances 0.000 description 1
- 210000001188 articular cartilage Anatomy 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 238000012219 cassette mutagenesis Methods 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- AVJBPWGFOQAPRH-FWMKGIEWSA-L dermatan sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@H](OS([O-])(=O)=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](C([O-])=O)O1 AVJBPWGFOQAPRH-FWMKGIEWSA-L 0.000 description 1
- 229940051593 dermatan sulfate Drugs 0.000 description 1
- 125000000600 disaccharide group Chemical group 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 102000013361 fetuin Human genes 0.000 description 1
- 108060002885 fetuin Proteins 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000000893 inhibin Substances 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 229940070376 protein Drugs 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000004153 renaturation Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Priority Applications (14)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19906096A DE19906096A1 (de) | 1999-02-13 | 1999-02-13 | Protein mit einem Heparin-bindenden Epitop |
| CA2362496A CA2362496C (en) | 1999-02-13 | 2000-01-27 | Polypeptide variants with increased heparin-binding ability |
| AU21106/00A AU762387B2 (en) | 1999-02-13 | 2000-01-27 | Polypeptide variants with raised heparin-binding capacity |
| DE50015938T DE50015938D1 (de) | 1999-02-13 | 2000-01-27 | Polypeptidvarianten mit erhoehter heparin-bindungsfaehigkeit |
| JP2000598634A JP4155711B2 (ja) | 1999-02-13 | 2000-01-27 | ヘパリン結合能の亢進したポリペプチド変異体 |
| BR0008785-8A BR0008785A (pt) | 1999-02-13 | 2000-01-27 | Variantes de polipeptìdeo com capacidade aumentada de ligação com a heparina |
| AT00901137T ATE470713T1 (de) | 1999-02-13 | 2000-01-27 | Polypeptidvarianten mit erhoehter heparin- bindungsfaehigkeit |
| PCT/EP2000/000637 WO2000047736A1 (de) | 1999-02-13 | 2000-01-27 | Polypeptidvarianten mit erhöhter heparin-bindungsfähigkeit |
| EP00901137A EP1151095B1 (de) | 1999-02-13 | 2000-01-27 | Polypeptidvarianten mit erhoehter heparin-bindungsfaehigkeit |
| US09/913,467 US7253254B1 (en) | 1999-02-13 | 2000-01-27 | Polypeptide variants with increased heparin-binding capacity |
| CNB008037183A CN1169959C (zh) | 1999-02-13 | 2000-01-27 | 高肝素结合力的多肽变异体 |
| RU2001123926/15A RU2227743C2 (ru) | 1999-02-13 | 2000-01-27 | Полипептидные варианты с повышенной гепаринсвязывающей способностью |
| JP2007258333A JP2008086319A (ja) | 1999-02-13 | 2007-10-02 | ヘパリン結合能の亢進したポリペプチド変異体 |
| JP2008201668A JP2009011323A (ja) | 1999-02-13 | 2008-08-05 | ヘパリン結合能の亢進したポリペプチド変異体 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19906096A DE19906096A1 (de) | 1999-02-13 | 1999-02-13 | Protein mit einem Heparin-bindenden Epitop |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE19906096A1 true DE19906096A1 (de) | 2000-08-17 |
Family
ID=7897433
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19906096A Ceased DE19906096A1 (de) | 1999-02-13 | 1999-02-13 | Protein mit einem Heparin-bindenden Epitop |
| DE50015938T Expired - Lifetime DE50015938D1 (de) | 1999-02-13 | 2000-01-27 | Polypeptidvarianten mit erhoehter heparin-bindungsfaehigkeit |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE50015938T Expired - Lifetime DE50015938D1 (de) | 1999-02-13 | 2000-01-27 | Polypeptidvarianten mit erhoehter heparin-bindungsfaehigkeit |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US7253254B1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1151095B1 (cg-RX-API-DMAC7.html) |
| JP (3) | JP4155711B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN1169959C (cg-RX-API-DMAC7.html) |
| AT (1) | ATE470713T1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU762387B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR0008785A (cg-RX-API-DMAC7.html) |
| CA (1) | CA2362496C (cg-RX-API-DMAC7.html) |
| DE (2) | DE19906096A1 (cg-RX-API-DMAC7.html) |
| RU (1) | RU2227743C2 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2000047736A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7981862B2 (en) | 2003-08-19 | 2011-07-19 | Biosurface Engineering Technologies, Inc. | Composition comprising BMP-2 amplifier/co-activator for enhancement of osteogenesis |
| EP1701729B1 (en) | 2003-12-31 | 2018-05-02 | Warsaw Orthopedic, Inc. | Improved bone matrix compositions and methods |
| US8734525B2 (en) | 2003-12-31 | 2014-05-27 | Warsaw Orthopedic, Inc. | Osteoinductive demineralized cancellous bone |
| JP4895826B2 (ja) * | 2004-02-20 | 2012-03-14 | バイオサーフェス エンジニアリング テクノロジーズ，インク． | 骨形成蛋白−２の正のモジュレーター |
| WO2006125868A1 (en) * | 2005-05-27 | 2006-11-30 | Bbs-Bioactive Bone Substitutes Oy | Bone morphogenetic proteins containing a heparin binding site and osteogenic devices and pharmaceutical products containing thereof |
| US7951384B2 (en) * | 2005-08-05 | 2011-05-31 | University Of Massachusetts | Virus-like particles as vaccines for paramyxovirus |
| US9216212B2 (en) | 2005-08-05 | 2015-12-22 | University Of Massachusetts | Virus-like particles as vaccines for paramyxovirus |
| WO2007053850A2 (en) | 2005-11-01 | 2007-05-10 | Osteotech, Inc. | Bone matrix compositions and methods |
| JP2007332106A (ja) * | 2006-06-16 | 2007-12-27 | Okayama Univ | 骨形成用徐放性医薬組成物 |
| US20080206299A1 (en) * | 2007-02-27 | 2008-08-28 | Shimp Lawrence A | Method for Recovering Minerals From Bone and Use of Same |
| CA2690457C (en) | 2007-06-15 | 2018-02-20 | Osteotech, Inc. | Bone matrix compositions and methods |
| US9554920B2 (en) | 2007-06-15 | 2017-01-31 | Warsaw Orthopedic, Inc. | Bone matrix compositions having nanoscale textured surfaces |
| US9358113B2 (en) | 2007-07-10 | 2016-06-07 | Warsaw Orthopedic, Inc. | Delivery system |
| JP2009045142A (ja) * | 2007-08-16 | 2009-03-05 | Okayama Univ | 生体内にて基材周囲に骨形成を誘導するための基材処理方法 |
| US8580270B2 (en) * | 2008-09-30 | 2013-11-12 | University Of Massachusetts | Respiratory synctial virus (RSV) sequences for protein expression and vaccines |
| WO2010071190A1 (ja) * | 2008-12-19 | 2010-06-24 | 国立大学法人 新潟大学 | ヘパリン親和性エリスロポエチン |
| WO2010093959A2 (en) | 2009-02-12 | 2010-08-19 | Osteotech, Inc. | Delivery systems, tools, and methods of use |
| GB201601136D0 (en) | 2016-01-21 | 2016-03-09 | Mörgelin Matthias And Abdillahi Suado M | Novel polypeptides and medical uses thereof |
| EP3562839A4 (en) | 2016-12-30 | 2020-09-02 | Biogend Therapeutics Co., Ltd. | RECOMBINANT POLYPEPTIDES, ASSOCIATED COMPOSITIONS AND PROCESSES |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996039430A1 (en) * | 1995-06-06 | 1996-12-12 | Hall Frederick L | TGF-β FUSION PROTEINS AND THEIR USE IN WOUND HEALING |
| DE19548476A1 (de) * | 1995-12-22 | 1997-06-26 | Bioph Biotech Entw Pharm Gmbh | Zielgerichtete Verbindungen mit knorpel- und/oder knocheninduzierender Aktivität |
Family Cites Families (76)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4455256A (en) | 1981-05-05 | 1984-06-19 | The Regents Of The University Of California | Bone morphogenetic protein |
| US4804744A (en) | 1984-01-04 | 1989-02-14 | International Genetic Engineering, Inc. | Osteogenic factors |
| NZ210699A (en) | 1984-01-04 | 1989-06-28 | Int Genetic Eng | Isolation of an osteogenic protein of the p3 immunologically related family |
| US4627982A (en) | 1984-07-16 | 1986-12-09 | Collagen Corporation | Partially purified bone-inducing factor |
| US5631142A (en) | 1986-07-01 | 1997-05-20 | Genetics Institute, Inc. | Compositions comprising bone morphogenetic protein-2 (BMP-2) |
| IL83003A (en) | 1986-07-01 | 1995-07-31 | Genetics Inst | Osteoinductive factors |
| US5106748A (en) | 1986-07-01 | 1992-04-21 | Genetics Institute, Inc. | Dna sequences encoding 5 proteins |
| US5013649A (en) | 1986-07-01 | 1991-05-07 | Genetics Institute, Inc. | DNA sequences encoding osteoinductive products |
| US6150328A (en) | 1986-07-01 | 2000-11-21 | Genetics Institute, Inc. | BMP products |
| US5459047A (en) | 1986-07-01 | 1995-10-17 | Genetics Institute, Inc. | BMP-6 proteins |
| US4877864A (en) | 1987-03-26 | 1989-10-31 | Genetics Institute, Inc. | Osteoinductive factors |
| US5366875A (en) | 1986-07-01 | 1994-11-22 | Genetics Institute, Inc. | Methods for producing BMP-7 proteins |
| US5187076A (en) | 1986-07-01 | 1993-02-16 | Genetics Institute, Inc. | DNA sequences encoding BMP-6 proteins |
| ZA874681B (en) | 1986-07-01 | 1988-04-27 | Genetics Inst | Novel osteoinductive factors |
| US4968590A (en) | 1988-04-08 | 1990-11-06 | Stryker Corporation | Osteogenic proteins and polypeptides |
| US5344654A (en) | 1988-04-08 | 1994-09-06 | Stryker Corporation | Prosthetic devices having enhanced osteogenic properties |
| US5354557A (en) | 1988-04-08 | 1994-10-11 | Stryker Corporation | Osteogenic devices |
| US5258494A (en) | 1988-04-08 | 1993-11-02 | Stryker Corporation | Osteogenic proteins |
| US5011691A (en) | 1988-08-15 | 1991-04-30 | Stryker Corporation | Osteogenic devices |
| US5250302A (en) | 1988-04-08 | 1993-10-05 | Stryker Corporation | Osteogenic devices |
| US5324819A (en) | 1988-04-08 | 1994-06-28 | Stryker Corporation | Osteogenic proteins |
| US5266683A (en) | 1988-04-08 | 1993-11-30 | Stryker Corporation | Osteogenic proteins |
| US4975526A (en) | 1989-02-23 | 1990-12-04 | Creative Biomolecules, Inc. | Bone collagen matrix for zenogenic implants |
| EP0723013B1 (en) | 1988-04-08 | 2003-06-18 | Stryker Corporation | Biosynthetic osteogenic proteins and osteogenic devices containing them |
| US4967737A (en) | 1988-08-03 | 1990-11-06 | Osteg Dyne Inc. | Method and device for treating bone disorders characterized by low bone mass |
| US5106626A (en) | 1988-10-11 | 1992-04-21 | International Genetic Engineering, Inc. | Osteogenic factors |
| US5510418A (en) | 1988-11-21 | 1996-04-23 | Collagen Corporation | Glycosaminoglycan-synthetic polymer conjugates |
| US4928959A (en) | 1988-12-16 | 1990-05-29 | Osteo-Dyne, Inc. | Method and device for providing active exercise treatment for a patient suffering from a bone disorder |
| EP0384731B1 (en) | 1989-02-23 | 1996-12-18 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Osteogenic growth polypeptides identified from regenerating bone marrow |
| EP0414915B1 (en) | 1989-03-06 | 1996-06-12 | Suntory Limited | New superoxide dismutase |
| CA2030518C (en) | 1989-03-28 | 2000-03-21 | Elizabeth A. Wang | Osteoinductive compositions |
| US5061786A (en) | 1989-05-25 | 1991-10-29 | Genentech, Inc. | Biologically active polypeptides based on transforming growth factor-β |
| CA2020729A1 (en) | 1989-07-19 | 1991-01-20 | Michael C. Kiefer | Bone morphogenetic protein |
| US5194596A (en) * | 1989-07-27 | 1993-03-16 | California Biotechnology Inc. | Production of vascular endothelial cell growth factor |
| ATE140965T1 (de) | 1989-09-06 | 1996-08-15 | Takeda Chemical Industries Ltd | Protein, dna und ihre verwendung |
| US5350836A (en) * | 1989-10-12 | 1994-09-27 | Ohio University | Growth hormone antagonists |
| JP2845346B2 (ja) | 1989-10-17 | 1999-01-13 | ストライカー・コーポレーション | 骨形成具 |
| GB8927546D0 (en) | 1989-12-06 | 1990-02-07 | Ciba Geigy | Process for the production of biologically active tgf-beta |
| DE69132823T2 (de) | 1990-05-16 | 2002-07-18 | Genetics Institute, Inc. | Knochen- und knorpel-bildung hervorrufende proteine |
| US5168050A (en) | 1990-05-24 | 1992-12-01 | Genentech, Inc. | Mammalian expression of the bone morphogenetic protein-2b using bmp2a/bmp2b fusion |
| US5645591A (en) | 1990-05-29 | 1997-07-08 | Stryker Corporation | Synthetic bone matrix |
| US5364839A (en) | 1990-06-18 | 1994-11-15 | Genetics Institute, Inc. | Osteoinductive pharmaceutical formulations |
| DK0643767T3 (da) | 1990-10-18 | 1999-04-26 | Stryker Corp | Osteogene peptider |
| WO1992009697A1 (en) | 1990-11-30 | 1992-06-11 | Celtrix Laboratories, Inc. | USE OF A BONE MORPHOGENETIC PROTEIN IN SYNERGISTIC COMBINATION WITH TGF-β FOR BONE REPAIR |
| US5652118A (en) | 1991-03-11 | 1997-07-29 | Creative Biomolecules, Inc. | Nucleic acid encoding a novel morphogenic protein, OP-3 |
| DK0575555T3 (da) | 1991-03-11 | 2001-11-05 | Curis Inc | Proteininduceret morfogenese |
| US6395883B1 (en) | 1991-03-11 | 2002-05-28 | Curis, Inc. | Soluble morphogenic protein complex compositions of matter |
| US5318898A (en) | 1991-04-02 | 1994-06-07 | Genetics Institute, Inc. | Production of recombinant bone-inducing proteins |
| KR0145278B1 (ko) | 1991-06-21 | 1998-07-15 | 브루스 엠. 에이센 | 골형성원 단백질 약제 |
| WO1993009229A1 (en) | 1991-11-04 | 1993-05-13 | Genetics Institute, Inc. | Recombinant bone morphogenetic protein heterodimers, compositions and methods of use |
| CA2129820C (en) | 1992-02-12 | 2003-06-17 | Helge Neidhardt | Dna sequences encoding novel growth/differentiation factors |
| US6120760A (en) | 1992-02-12 | 2000-09-19 | Biopharm Gesellschaft Zur Biotechnologischen Entwicklung | Growth/differentiation factors of the TGF-β family |
| US6180602B1 (en) | 1992-08-04 | 2001-01-30 | Sagami Chemical Research Center | Human novel cDNA, TGF-beta superfamily protein encoded thereby and the use of immunosuppressive agent |
| WO1994015949A1 (en) | 1993-01-12 | 1994-07-21 | Johns Hopkins University School Of Medicine | Growth differentiation factor-5 |
| IL104954A (en) | 1993-03-04 | 2006-08-01 | Yissum Res Dev Co | Use of osteogenic oligopeptides in the preparation of pharmaceutical compositions for the treatment of bone diseases and some such novel oligopeptides, pharmaceutical compositions containing them and their preparation |
| US5652332A (en) * | 1993-03-12 | 1997-07-29 | Xoma | Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof |
| IL108947A0 (en) | 1993-03-12 | 1994-06-24 | Osteopharm Ltd | Bone stimulating factor |
| ES2201076T3 (es) | 1993-03-19 | 2004-03-16 | The Johns Hopkins University School Of Medicine | Factor-8 de diferenciacion del crecimiento. |
| US5637480A (en) | 1993-05-12 | 1997-06-10 | Genetics Institute, Inc. | DNA molecules encoding bone morphogenetic protein-10 |
| JPH09503903A (ja) | 1993-07-09 | 1997-04-22 | ザ ジョーンズ ホプキンス ユニバーシティー スクール オブ メディシン | 増殖分化因子−６ |
| IL110589A0 (en) | 1993-08-10 | 1994-11-11 | Bioph Biotech Entw Pharm Gmbh | Growth/differentiation factor of the TGF- beta family |
| US5385887A (en) | 1993-09-10 | 1995-01-31 | Genetics Institute, Inc. | Formulations for delivery of osteogenic proteins |
| US5399677A (en) | 1993-12-07 | 1995-03-21 | Genetics Institute, Inc. | Mutants of bone morphogenetic proteins |
| TW440566B (en) | 1994-07-25 | 2001-06-16 | Novartis Ag | Novel process for the production of biologically active dimeric protein |
| US5707962A (en) | 1994-09-28 | 1998-01-13 | Gensci Regeneration Sciences Inc. | Compositions with enhanced osteogenic potential, method for making the same and therapeutic uses thereof |
| US6180606B1 (en) | 1994-09-28 | 2001-01-30 | Gensci Orthobiologics, Inc. | Compositions with enhanced osteogenic potential, methods for making the same and uses thereof |
| US5782919A (en) | 1995-03-27 | 1998-07-21 | Sdgi Holdings, Inc. | Interbody fusion device and method for restoration of normal spinal anatomy |
| US5739277A (en) | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
| US5902785A (en) | 1995-06-06 | 1999-05-11 | Genetics Institute, Inc. | Cartilage induction by bone morphogenetic proteins |
| ZA966489B (en) | 1995-08-03 | 1997-02-26 | Bioph Biotech Entw Pharm Gmbh | New protein human MP52 Arg. |
| JP2000506375A (ja) | 1996-01-26 | 2000-05-30 | エイチエスシー リサーチ アンド デベロップメント リミテッド パートナーシップ | アルツハイマー病に関連する核酸およびタンパク質、ならびにその使用 |
| US5877153A (en) * | 1996-06-11 | 1999-03-02 | Commonwealth Biotechnologies Inc. | Heparin-binding peptides |
| ES2297852T3 (es) | 1996-10-08 | 2008-05-01 | University Of Washington | Aplicaciones terapeuticas de laminina y de fragmentos proteicos obtenidos a partir de laminina. |
| US6080779A (en) | 1996-12-13 | 2000-06-27 | Osteoscreen, Inc. | Compositions and methods for stimulating bone growth |
| US6894022B1 (en) * | 1998-08-27 | 2005-05-17 | Eidgenossische Technische Hochschule Zurich | Growth factor modified protein matrices for tissue engineering |
| AU2001251507A1 (en) | 2000-04-11 | 2001-10-23 | Cogent Neuroscience, Inc. | Compositions and methods for diagnosing and treating conditions, disorders, or diseases involving cell death |
-
1999
- 1999-02-13 DE DE19906096A patent/DE19906096A1/de not_active Ceased
-
2000
- 2000-01-27 AT AT00901137T patent/ATE470713T1/de not_active IP Right Cessation
- 2000-01-27 BR BR0008785-8A patent/BR0008785A/pt not_active Application Discontinuation
- 2000-01-27 US US09/913,467 patent/US7253254B1/en not_active Expired - Fee Related
- 2000-01-27 JP JP2000598634A patent/JP4155711B2/ja not_active Expired - Fee Related
- 2000-01-27 DE DE50015938T patent/DE50015938D1/de not_active Expired - Lifetime
- 2000-01-27 WO PCT/EP2000/000637 patent/WO2000047736A1/de not_active Ceased
- 2000-01-27 EP EP00901137A patent/EP1151095B1/de not_active Expired - Lifetime
- 2000-01-27 AU AU21106/00A patent/AU762387B2/en not_active Ceased
- 2000-01-27 RU RU2001123926/15A patent/RU2227743C2/ru not_active IP Right Cessation
- 2000-01-27 CN CNB008037183A patent/CN1169959C/zh not_active Expired - Fee Related
- 2000-01-27 CA CA2362496A patent/CA2362496C/en not_active Expired - Fee Related
-
2007
- 2007-10-02 JP JP2007258333A patent/JP2008086319A/ja active Pending
-
2008
- 2008-08-05 JP JP2008201668A patent/JP2009011323A/ja active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996039430A1 (en) * | 1995-06-06 | 1996-12-12 | Hall Frederick L | TGF-β FUSION PROTEINS AND THEIR USE IN WOUND HEALING |
| DE19548476A1 (de) * | 1995-12-22 | 1997-06-26 | Bioph Biotech Entw Pharm Gmbh | Zielgerichtete Verbindungen mit knorpel- und/oder knocheninduzierender Aktivität |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2000047736A1 (de) | 2000-08-17 |
| EP1151095B1 (de) | 2010-06-09 |
| CN1169959C (zh) | 2004-10-06 |
| JP4155711B2 (ja) | 2008-09-24 |
| CA2362496A1 (en) | 2000-08-17 |
| JP2002536016A (ja) | 2002-10-29 |
| JP2009011323A (ja) | 2009-01-22 |
| AU762387B2 (en) | 2003-06-26 |
| US7253254B1 (en) | 2007-08-07 |
| ATE470713T1 (de) | 2010-06-15 |
| CA2362496C (en) | 2011-04-19 |
| BR0008785A (pt) | 2001-11-06 |
| JP2008086319A (ja) | 2008-04-17 |
| AU2110600A (en) | 2000-08-29 |
| DE50015938D1 (de) | 2010-07-22 |
| CN1340102A (zh) | 2002-03-13 |
| RU2227743C2 (ru) | 2004-04-27 |
| EP1151095A1 (de) | 2001-11-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE19906096A1 (de) | Protein mit einem Heparin-bindenden Epitop | |
| DE3752364T2 (de) | Osteoinduktive Zusammensetzungen | |
| DE69231946T2 (de) | Protein-induzierende morphogenese | |
| DE69031939T2 (de) | Osteoinduktive zusammensetzungen | |
| DE69032424T2 (de) | Osteogene vorrichtungen | |
| DE68927995T2 (de) | Osteogene faktoren | |
| DE69528128T2 (de) | Rekombinante Chimäre Proteine und Verfahren zur deren Verwendung | |
| DE69434538T2 (de) | Vaskulärer endothelialer Wachstumsfaktor 2 | |
| DE69101316T2 (de) | Empfänglichmachen von säugetieren für beschleunigte gewebereparatur. | |
| Hofer et al. | Brain-derived neurotrophic factor prevents neuronal death in vivo | |
| DE69129865T2 (de) | Osteogene peptide | |
| DE69528058T2 (de) | Bmp-9 zusammensetzungen | |
| DE69433742T2 (de) | Bmp-10 zusammensetzungen | |
| DE69737809T2 (de) | Methoden zur herstellung von op-1 morphogen analoge | |
| DE69233022T2 (de) | Rekombinante knochenmorphogenetische protein heterodimere, zusammensetzungen und verfahren zur verwendung | |
| EP0713529B1 (de) | Wachstums-Differenzierungsfaktor der TGF-B Familie | |
| DE60021388T2 (de) | Monomeres protein der tgf-beta familie | |
| DE69936312T2 (de) | Mutanten von op-1 | |
| DE69533698T2 (de) | Pantropische Neurotropische Faktoren | |
| DE3877753T2 (de) | Transformierender wachstumsfaktor-beta. | |
| DE69133338T2 (de) | Bmp-5-derivate | |
| DE69619860T2 (de) | Verfahren zur herstellung aktiver substanzen aus perlmutt, resultierende produkte, geeignet für medizinische anwendungen | |
| EP0557498A1 (de) | Knochenwachstumsfördernde zusammensetzung | |
| DE69122472T2 (de) | Neurotropische wachstumsfaktoren, die ein homeobox-peptid enthalten | |
| DE69428013T2 (de) | Strukturanaloge von Fibroblasten-Wachstumsfaktoren, die eine modifizierte Heparin-Bindungsstelle aufweisen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| OM8 | Search report available as to paragraph 43 lit. 1 sentence 1 patent law | ||
| 8110 | Request for examination paragraph 44 | ||
| 8127 | New person/name/address of the applicant |
Owner name: OSTEOPHARMA INC., OSAKA, JP |
|
| 8181 | Inventor (new situation) |
Inventor name: SEBALD, WALTER PROF. DR., 97074 WUERZBURG, DE |
|
| R002 | Refusal decision in examination/registration proceedings | ||
| R003 | Refusal decision now final |
Effective date: 20121113 |